Bristol-Myers
Squibb BMY today announced that the European
Medicines Agency (EMA) has validated the company's marketing
authorization application (MAA) for the use of daclatasvir (DCV), an
investigational NS5A complex inhibitor, for the treatment of adults with
chronic hepatitis C (HCV) with compensated liver disease, including
genotypes 1, 2, 3, and 4. The application seeks the approval of
daclatasvir for use in combination with other agents, including
sofosbuvir, for the treatment of chronic hepatitis C. The MAA validation
marks the start of an accelerated regulatory review process for DCV,
which has the potential, when used in combination with other agents, to
address a high unmet need in the European Union (EU), where an estimated
9
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in